Teriparatide
Evidence: A — Established Human EvidenceHormone / Fertility
Evidence Snapshot
Regulatory Context
FDA-approved in multiple finished products for defined osteoporosis populations at high risk for fracture.
Research Takeaway
Teriparatide is recombinant human parathyroid hormone 1-34, a 34-amino-acid peptide identical to the biologically active N-terminal region of human PTH; it is distinct from full-length PTH(1-84) and from abaloparatide.
Evidence boundary: Shared PTH-receptor biology does not make these molecular entities interchangeable.
See all 6 evidence claims →Quick Summary
Teriparatide is recombinant human parathyroid hormone 1-34 (PTH(1-34)), FDA-approved in multiple finished products, including Forteo, for defined osteoporosis populations at high risk of fracture. It is distinct from full-length PTH(1-84) and from abaloparatide.
Mechanism & Research Overview
Teriparatide is recombinant human parathyroid hormone 1-34 (PTH(1-34)), FDA-approved in multiple finished products, including Forteo, for defined osteoporosis populations at high risk of fracture. It is distinct from full-length PTH(1-84) and from abaloparatide.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Teriparatide is recombinant human parathyroid hormone 1-34, a 34-amino-acid peptide identical to the biologically active N-terminal region of human PTH; it is distinct from full-length PTH(1-84) and from abaloparatide.
Does not establish
Evidence boundary: Shared PTH-receptor biology does not make these molecular entities interchangeable.
Supported
Teriparatide is FDA-approved in multiple finished drug products for defined osteoporosis populations at high risk for fracture.
Does not establish
Evidence boundary: This approval does not establish bodybuilding, fracture-healing enhancement in otherwise healthy people, or nonspecific bone-strengthening use.
Supported
Randomized fracture-prevention evidence demonstrates reduced vertebral and selected nonvertebral fracture risk in high-risk osteoporosis populations treated with teriparatide.
Does not establish
Evidence boundary: Fracture-risk reduction in osteoporosis does not establish benefit in people without an osteoporosis indication.
Supported
Teriparatide labeling includes clinically important risks and precautions involving hypercalcemia, orthostatic symptoms, urolithiasis-related considerations, and osteosarcoma-risk context.
Does not establish
Evidence boundary: This is not an exhaustive safety summary and does not replace the current prescribing information.
Supported
Evidence from FDA-approved teriparatide products cannot be transferred automatically to unapproved grey-market PTH(1-34) vials because identity, potency, purity, sterility, and delivery accuracy may differ.
Does not establish
Evidence boundary: This does not assert that a specific unapproved vial is counterfeit; it states that therapeutic equivalence is unestablished.
Supported
Only exact FDA-label or named clinical-trial dosing may appear as Study/Trial Dosing; no consumer bone-building, fracture-recovery, reconstitution, or injection recommendations may be created.
Does not establish
Evidence boundary: Prescription-label dosing is not individualized guidance.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Research Areas Being Studied
Research areas discussed on this page reflect the Hormone / Fertility category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
No Sources Listed Yet
Human, preclinical, regulatory, and review sources will appear here as they are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated .
Follow research updates for Teriparatide
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.